|
May 14
|
Immatics Announces First Quarter 2024 Financial Results and Business Update
|
|
Mar 21
|
Immatics Announces Full Year 2023 Financial Results and Corporate Update
|
|
Mar 15
|
With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
|
|
Jan 18
|
Immatics Announces Pricing of $175 Million Public Offering
|
|
Jan 17
|
Immatics Announces Proposed Public Offering
|
|
Jan 16
|
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
|
|
Nov 30
|
Levicept Appoints Eliot Forster as CEO
|
|
Nov 8
|
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
|
|
Nov 2
|
Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans
|
|
Apr 23
|
TipRanks ‘Perfect 10’ List: These 2 Top-Rated Stocks Could Be Long-Term Winners
|